Sign In
Buy STTK
$4.75
-0.120 (-2.46%)
At Close: Jun 03, 2026
AUSTIN, TX and DURHAM, NC, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion pro
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
07:00am, Monday, 08'th Jan 2024
AUSTIN, TX and DURHAM, NC, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
04:05pm, Thursday, 04'th Jan 2024
AUSTIN, TX and DURHAM, NC, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr
Shattuck Labs: Positive Blood Cancer Data Leads To Mid-2024 Catalyst
06:58pm, Thursday, 21'st Dec 2023
Positive results were released from the phase 1A/B study, using SL-172154 in combination with azacitidine for the treatment of patients with front-line higher-risk myelodysplastic syndrome and TP53 mu
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
08:00am, Thursday, 21'st Dec 2023
AUSTIN, TX and DURHAM, NC, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development
Why Is Shattuck Labs (STTK) Stock Up 93% Today?
10:45am, Wednesday, 13'th Dec 2023
Shattuck Labs (NASDAQ: STTK ) stock is on the rise Wednesday after the clinical-stage biotechnology company announced results from an ongoing Phase 1a/b trial. These clinical trials cover the use of S
– Observed 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete response (CR)/marrow complete response (mCR) rate of 64% –
AUSTIN, TX and DURHAM, NC, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr
Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference
09:00am, Tuesday, 14'th Nov 2023
AUSTIN, TX & DURHAM, NC, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot
Shattuck Labs, Inc. (STTK) Q3 2023 Earnings Call Transcript
02:45pm, Friday, 10'th Nov 2023
Shattuck Labs, Inc. (NASDAQ:STTK ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Conor Richardson – Vice President-Investor Relations Taylor Schreiber – Scienti
Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023
09:28am, Monday, 06'th Nov 2023
AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion p
Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue Estimates
06:16pm, Thursday, 10'th Aug 2023
Shattuck Labs, Inc. (STTK) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.65 per share a year ago.
- SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose �
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates
06:20pm, Tuesday, 09'th May 2023
Shattuck Labs, Inc. (STTK) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.58 per share a year ago.
7 Very Undervalued Penny Stocks to Buy in April 2023
05:39pm, Thursday, 06'th Apr 2023
Investors are attracted to penny stocks for their potential to provide exponential gains. It is very common to find such companies trading for fractions of their target price.
